ArticleBritish journal of haematology2026

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

Michael Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.